Related Experiment Video

Updated: Feb 19, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma

Ashutosh Chauhan1,2, Deepak Kumar Semwal3, Satyendra Prasad Mishra4

  • 1Department of Urology, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, India. ashutosh_biotech2006@yahoo.com.

Medical Sciences (Basel, Switzerland)
|October 31, 2017
PubMed

Insights

Targeted therapies improve survival for kidney cancer (Renal Cell Carcinoma, RCC), but resistance emerges. Inhibiting both mTOR and MAPK pathways may offer better outcomes for advanced RCC patients.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Renal Cell Carcinoma (RCC) is the most common kidney cancer with unique biology and poor response to traditional treatments.
  • Recent advancements have introduced targeted therapies for metastatic RCC, improving overall survival but not offering a cure.
  • Current targeted therapies face challenges like adverse events, non-response, and acquired resistance.

Purpose of the Study:

  • To address the limitations of current targeted therapies in advanced Renal Cell Carcinoma.
  • To investigate the potential of combined inhibition of Mammalian target of Rapamycin (mTOR) and Mitogen-Activated Protein Kinase (MAPK) pathways.

Main Methods:

  • Review of studies on targeted therapies for advanced RCC.
  • Analysis of mechanisms of resistance to mTOR inhibitors, including MAPK pathway activation.
  • Exploration of combination therapy strategies targeting both mTOR and MAPK pathways.

Main Results:

  • mTOR pathway inhibitors are used in advanced RCC treatment.
  • Inhibition of mTOR signaling can lead to MAPK pathway activation, causing resistance to mTOR inhibitors.
  • Combined inhibition strategies are being explored to overcome resistance and improve treatment efficacy.

Conclusions:

  • Targeted therapies have improved outcomes for metastatic RCC but do not provide a cure.
  • Resistance to mTOR inhibitors develops due to MAPK pathway activation.
  • Simultaneous inhibition of both mTOR and MAPK pathways presents a promising strategy for improved management of advanced RCC.
Keywords:
mammalian target of rapamycinmitogen activated protein kinaserenal cell carcinomatarget therapy

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K